AI for PE-Backed Life Sciences

Your portfolio companies have AI tools. Do they have AI results?

Most don’t. I turn AI spend into EBITDA impact, for PE-backed life sciences, pharma, and MedTech across Europe.

Request a Portfolio Assessment
★★★★★ 5.0 / 5, 100% recommendation rate on ProvenExpert
Regulated Industries Pharma & MedTech EBITDA Focus Responsible AI
0
use cases mapped to EUR impact in one engagement
0
recoverable annual capacity documented
0
first quick win live
0
digital transformation across 9 industries
The Pattern

Every portfolio company I've assessed had AI tools. None had AI results.

The tools were there. The processes hadn’t changed. 300K+ EUR in recoverable annual capacity was sitting across seven departments, undocumented, unquantified, invisible to the board.

What Operating Partners Actually Want

A number for the board.
Not another AI project to manage.

  • Tell me which portfolio companies should invest in AI, and which shouldn’t. Done.
  • Give me one person who talks to the GM and delivers the result. No escalation.
  • Hand me an EBITDA number I can put in front of the IC, and everyone believes it.

That’s what I deliver.

Ways to Work Together

AI Advisor, Board Advisor, Keynote Speaker.

01

AI Advisor for PE Portfolios

Embedded AI leadership for PE-backed life sciences companies. From assessment to implementation to documented results.

02

Board & Fund Advisory

AI governance, vendor evaluation, and technology due diligence for operating partners and boards.

03

Keynotes

Keynotes and panels for PE summits, offsites, board sessions, and industry conferences.

Keynotes page →
Built-In Compliance

AI that passes the board meeting and the audit.

Regulated Industries

15+ years operating in pharma, MedTech and life sciences. Auditability and risk-aversion are designed in from day one.

Specialist Network

Deep legal and compliance questions go to specialists in the network. AI strategy stays where it belongs: with one accountable senior advisor.

Human in the Loop

Every AI workflow includes human oversight, escalation paths, and clear accountability.

Audit-Ready

Full documentation trail. Ready for internal audit, external review, or LP reporting.

Regulated Industries

15+ years operating in pharma, MedTech and life sciences. Auditability and risk-aversion are designed in from day one.

Specialist Network

Deep legal and compliance questions go to specialists in the network. AI strategy stays where it belongs: with one accountable senior advisor.

Human in the Loop

Every AI workflow includes human oversight, escalation paths, and clear accountability.

Audit-Ready

Full documentation trail. Ready for internal audit, external review, or LP reporting.

Engagements

Recent work

Specialty Pharma · PE-Backed

24 use cases. 7 departments. Board-approved roadmap in the same quarter.

Three-day workshop across all functions. Voice documentation, order processing automation, GDPR-compliant knowledge systems, deployed, not just recommended.

24use cases mapped
3 daysto deliverable
Life Sciences Portfolio · PE Sponsor

300K+ EUR recoverable annual capacity. Quick wins live in month 1.

Seven functions assessed and quantified in EUR. Insurance claims automation, prescription intake workflows, AI-assisted documentation. MDR and GDPR compliant.

300K+ EURannual capacity
Month 1first wins live
About
Karolyne Hahn

Nine years advising C-level leaders on digital transformation, across aerospace and defence, chemicals, telecommunications, life sciences, and financial services. Then I narrowed the focus to where AI changes the most: regulated industries with high operational density. I've led AI programmes for PE-backed specialty pharma, trained leadership teams across seven departments, and built the workflows myself when no one else would.

Most companies separate AI strategy from AI implementation. I don't.

Karolyne Hahn, Munich

FAQs
How can AI advisory help my portfolio?

I analyse your portfolio companies’ specific challenges, identify high-value AI use cases, and develop tailored solutions. Through a “strategy by doing” approach, you don’t get concepts, you get measurable results that show up in the value creation plan. If needed, I enable the portfolio company’s team to continue independently.

What if portfolio companies already have AI tools?

Most do. The problem is rarely the tools, it’s that processes haven’t changed around them. I assess what’s there, identify what’s actually delivering value, what should be replaced, and close the gap between AI spend and AI results.

How is this different from hiring a consulting firm?

No junior team. No 80-page deck before anything happens. I develop the AI strategy not in an ivory tower, but through concrete prototypes and quick wins inside your portfolio companies. One senior person, directly accountable to you, not to a partner at a firm.

What does it cost?

It depends on the format. A portfolio assessment is a fixed fee. Pilots and advisory retainers are monthly. Everything is modular, you start where it makes sense and scale from there. I provide a transparent proposal after an initial conversation. No surprises.

What does the engagement look like in practice?

I work on a retained basis. Hands-on when it matters, async support throughout, calls when needed, not a standing calendar invite nobody wants. C-level-grade AI leadership focused on EBITDA impact, delivered sustainably and transparently, without the full-time cost.

How long does a typical engagement last?

It depends on where you start. A portfolio-level assessment takes two weeks. A workshop runs one to three days. A pilot engagement runs 90 days. Advisory retainers typically run 6–12 months, rolling, until the results speak for themselves and you no longer need me.

How do you handle regulatory complexity?

I’ve worked in regulated industries for 15+ years and design AI implementations with auditability and risk-aversion in mind. For deep regulatory interpretation, I bring in specialists from my network: I am the AI strategist, not the compliance lawyer.

What is your approach to Responsible AI?

Responsible AI is not an add-on, it’s how I advise. Whether I sit on the advisory board or work directly with the portfolio company, risk classification, transparency, and human oversight are built into every recommendation. This creates trust with boards, regulators, and LPs, and increasingly, it’s a competitive advantage at exit.

Next Step

Walk into your next board meeting with a number.

Start with a two-week portfolio assessment. Fixed fee. No obligation to continue. Tell me where you suspect the biggest untapped capacity, and I’ll show you the numbers.

The most direct route. A few lines on the portfolio and where capacity is leaking.

mail@karolynehahn.com
LocationMunich, Germany
FocusDACH & Europe